C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio et al., Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-330, 2015.
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00699117

J. Larkin, D. Minor, D. Angelo, S. Neyns, B. Smylie et al., Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator???s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial, Journal of Clinical Oncology, vol.36, issue.4, pp.383-390, 2018.
DOI : 10.1200/JCO.2016.71.8023

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. Grob, C. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015.
DOI : 10.1056/NEJMoa1504030
URL : http://www.zora.uzh.ch/id/eprint/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf

A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid et al., Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, The Lancet Oncology, vol.16, issue.8, pp.908-918, 2015.
DOI : 10.1016/S1470-2045(15)00083-2

C. Robert, J. Schachter, G. Long, A. Arance, J. Grob et al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2532, 2015.
DOI : 10.1056/NEJMoa1503093

P. Tumeh, C. Harview, J. Yearley, I. Shintaku, E. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.15, issue.7528, pp.568-571, 2014.
DOI : 10.1158/1078-0432.CCR-09-1624
URL : http://europepmc.org/articles/pmc4246418?pdf=render

A. Daud, K. Loo, M. Pauli, R. Sanchez-rodriguez, P. Sandoval et al., Tumor immune profiling predicts response to anti???PD-1 therapy in human melanoma, Journal of Clinical Investigation, vol.126, issue.9, pp.3447-3452, 2016.
DOI : 10.1172/JCI87324DS2
URL : http://europepmc.org/articles/pmc5004965?pdf=render

P. Chen, W. Roh, A. Reuben, Z. Cooper, C. Spencer et al., Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade, Cancer Discovery, vol.6, issue.8, pp.827-837, 2016.
DOI : 10.1158/2159-8290.CD-15-1545

K. Loo, K. Tsai, K. Mahuron, J. Liu, M. Pauli et al., Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy, JCI Insight, vol.2, issue.14, p.93433, 2017.
DOI : 10.1172/jci.insight.93433
URL : http://insight.jci.org/articles/view/93433/files/pdf

G. Gibney, L. Weiner, and M. Atkins, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, The Lancet Oncology, vol.17, issue.12, pp.542-551, 2016.
DOI : 10.1016/S1470-2045(16)30406-5
URL : http://europepmc.org/articles/pmc5702534?pdf=render

F. Hodi, J. Chesney, A. Pavlick, C. Robert, K. Grossmann et al., Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, The Lancet Oncology, vol.17, issue.11, pp.1558-1568, 2016.
DOI : 10.1016/S1470-2045(16)30366-7
URL : http://europepmc.org/articles/pmc5630525?pdf=render

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7420, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

L. Seymour, J. Bogaerts, A. Perrone, R. Ford, L. Schwartz et al., iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, The Lancet Oncology, vol.18, issue.3, pp.143-152, 2017.
DOI : 10.1016/S1470-2045(17)30074-8
URL : http://europepmc.org/articles/pmc5648544?pdf=render

A. Knol, A. Vallee, G. Herbreteau, J. Nguyen, E. Varey et al., Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline, Experimental Dermatology, vol.22, issue.10, pp.783-788, 2016.
DOI : 10.1158/1078-0432.CCR-15-1031
URL : https://hal.archives-ouvertes.fr/inserm-01408920

A. Santiago-walker, R. Gagnon, J. Mazumdar, M. Casey, G. Long et al., Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials, Clinical Cancer Research, vol.22, issue.3, pp.567-574, 2016.
DOI : 10.1158/1078-0432.CCR-15-0321

M. Sanmamed, S. Fernandez-landazuri, C. Rodriguez, R. Zarate, M. Lozano et al., Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors, Clinical Chemistry, vol.61, issue.1, pp.297-304, 2015.
DOI : 10.1373/clinchem.2014.230235

J. Lee, G. Long, S. Boyd, S. Lo, A. Menzies et al., Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma, Annals of Oncology, vol.6, issue.5
DOI : 10.1158/2159-8290.CD-15-1336

M. Schreuer, G. Meersseman, S. Van-den-herrewegen, Y. Jansen, I. Chevolet et al., Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors, Journal of Translational Medicine, vol.24, issue.6, p.95, 2016.
DOI : 10.1038/cr.2014.44

A. Marchetti, J. Palma, L. Felicioni, D. Pas, T. Chiari et al., Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients, Journal of Thoracic Oncology, vol.10, issue.10, pp.1437-1443, 2015.
DOI : 10.1097/JTO.0000000000000643

T. Mok, Y. Wu, J. Lee, C. Yu, V. Sriuranpong et al., Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy, Clinical Cancer Research, vol.21, issue.14, pp.3196-3203, 2015.
DOI : 10.1158/1078-0432.CCR-14-2594

A. Chaudhuri, J. Chabon, A. Lovejoy, A. Newman, H. Stehr et al., Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling, Cancer Discovery, vol.7, issue.12, pp.1394-1403, 2017.
DOI : 10.1158/2159-8290.CD-17-0716

J. Tie, Y. Wang, C. Tomasetti, L. Li, S. Springer et al., Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Science Translational Medicine, vol.52, issue.346, pp.346-92, 2016.
DOI : 10.1111/j.0006-341X.2000.00337.x

I. Garcia-murillas, G. Schiavon, B. Weigelt, C. Ng, S. Hrebien et al., Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer, Science Translational Medicine, vol.23, issue.302, pp.302-133, 2015.
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

J. Lee, G. Long, A. Menzies, S. Lo, A. Guminski et al., Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti???Programmed Cell Death 1 Antibodies, JAMA Oncology, vol.4, issue.5, 2018.
DOI : 10.1001/jamaoncol.2017.5332

J. Remon, J. Menis, B. Hasan, A. Peric, D. Maio et al., The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613, Clinical Lung Cancer, vol.18, issue.5, pp.583-588, 2017.
DOI : 10.1016/j.cllc.2017.02.005